Full access
Clinical & Research News
Published Online: 16 November 2012

New Target Emerges in Search for Alzheimer’s Treatment

Joan Arehart-TreichelAuthors Info & Affiliations
Publication: Psychiatric News
Volume 47, Number 22
https://doi.org/10.1176/pn.47.22.psychnews_47_22_22-a

Abstract

Although cholesterol-lowering drugs can’t treat Alzheimer’s disease in individuals with high cholesterol levels, a drug that targets IgG antibody receptors might be able to do so.
Several recent clinical trials involving compounds designed to reduce amyloid plaques in the brain—the hallmark of Alzheimer’s disease (AD)—have failed to counter the illness. Thus, to successfully treat Alzheimer’s, it might be necessary to target other factors contributing to the disease as well.
Three possible candidates are cholesterol, which is a risk factor for AD, as well as IgG antibodies and receptors for IgG antibodies, researchers reported in the September Brain.
The lead scientist was Paula Fernandez-Vizarra, Ph.D., of Germany’s Max Planck Institute of Psychiatry.
She and her colleagues studied mice genetically engineered to have high blood levels of cholesterol. These mice also displayed several neuropathological hallmarks of AD—high levels of amyloid precursor protein and beta amyloid, abnormal tau hyperphosphorylation, and learning and memory impairments.
The researchers found, in the brains of these mice, heightened levels of IgG antibodies and heightened levels of receptors for IgG antibodies in neurons susceptible to amyloid accumulation. Moreover, they discovered that genetically altering these receptors so that they couldn’t function reduced amyloid deposits and abnormal tau hyperphosphorylation and prevented learning and memory impairments.
They thus believe that IgG antibodies and IgG antibody receptors in the brain may contribute to the development of amyloid accumulation and, in turn, Alzheimer’s in individuals with high blood levels of cholesterol. They also suspect that this might be the case because AD patients are known to produce elevated levels of IgG antibodies against nonbrain antigens and to express receptors for these antibodies in neuronal populations vulnerable to AD.
As a result, the researchers suggested that IgG receptors may constitute “a new potential target for slowing or preventing Alzheimer’s disease” in individuals with high cholesterol levels, especially since simply giving human subjects with high cholesterol levels cholesterol-lowering drugs has not proven effective at countering AD.
The study was funded by the Spanish Ministry of Science, several other Spanish organizations, and the Lilly Foundation.
An abstract of “Immunoglobulin G Fc Receptor Deficiency Prevents Alzheimer-like Pathology and Cognitive Impairment in Mice” is posted at http://brain.oxfordjournals.org/content/135/9/2826.abstract.

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 47 • Number 22 • November 16, 2012
Pages: 22 - 28

History

Published online: 16 November 2012
Published in print: November 16, 2012

Authors

Affiliations

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.